Publikationen in Zusammenarbeit mit Forschern von University of Leeds (7)

2024

  1. The evolving value assessment of cancer therapies: Results from a modified Delphi study

    Health Policy OPEN, Vol. 6

2022

  1. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial

    JAMA Oncology, Vol. 8, Núm. 7, pp. 1047-1052

2015

  1. "New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

    Breast Cancer Research, Vol. 17, Núm. 1

  2. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): A randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 15, pp. 1556-1568

  3. Recognizing the place of trials with treatment of physician's choice as the control Arm

    Journal of Clinical Oncology

2014

  1. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer

    Oncologist, Vol. 19, Núm. 4, pp. 318-327

2011

  1. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study

    The Lancet, Vol. 377, Núm. 9769, pp. 914-923